All Comments by Lon S. Schneider
- TauRx Parses Subgroups to Make the Case for Methylene Blue Derivative, Again
- Adieu to Aduhelm: Biogen Stops Marketing Antibody
- And Then There Were Three: Donanemab Phase 3 Trial Positive
- What About the Brain Shrinkage Seen with Aβ Removal?
- No Easy Answers on Clinical Meaningfulness of Alzheimer’s Treatments
- Did Dementia Patient Care Go Downhill During the COVID Pandemic?
- Gantenerumab Falls Short in Phase 3
- Finally: Big Win on All Outcomes for Lecanemab in Phase 3 Topline Results
- Could Benefit of Plaque Removal Grow in Time?
- TAURIEL Phase 2 Data Published
- On Aduhelm, Medicare Agency Gets Pressure From All Sides
- CMS Plans to Limit Aduhelm Coverage to Clinical Trials
- Aduhelm Phase 3 Data: ARIA Is Common, Sometimes Serious
- On Donanemab, Plaques Plummet. Off Donanemab, They Stay Away
- Aducanumab Approved to Treat Alzheimer’s Disease